New Combination Therapy Looks Promising Against Ulcer Bacteria
Posted on: Monday, 26 October 2009, 22:50 CDT
Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.
Results of a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology reveal LOAD therapy is superior to LAC at eliminating the bacterium in patients with gastritis and peptic ulcers. Moreover, Dr. Patrick Basu and his colleagues at Columbia University College of Physicians and Surgeons found that a shorter course of the four-drug combination, seven days vs. a ten-day treatment, is equally effective.
The study included 135 patients with treatment naïve Helicobacter pylori infection who were randomized to LOAD (7 or 10 days) vs. LAC (10 days). There was a total wash out period of six weeks from any prior antibiotic and PPI use prior to the initiation of therapy.
"H. pylori gastritis is a global threat for gastric carcinoma and many therapies have been explored to eradicate this infection with variable success rates," explained Dr. Basu. "Our study demonstrates the therapeutic superiority of LOAD therapy over LAC therapy in a treatment naïve population of patients with H. pylori."
---
On the Net:
Related Articles
- Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
- ZIOPHARM Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide
- Beaumont Patients 1st to Get Next Generation of Radiation Treatment
- First Patient Enrolled in SONOMA Post-Market Approval Study of Boston Scientific NexStent(R) Carotid Stent System and FilterWire EZ(TM) Embolic Protection Device
- Medtronic Announces Start of Two Clinical Trials Studying Treatment of Thoracic Aortic Aneurysms and Dissections
- Bioenvision's Suvus(TM) Lowers Viral Load in Chronic Hepatitis C; Randomized Study Data Presented at Scientific Conference
- Chinese Experts Convene to Study Treatment of Human Bird Flu.
- Most End-Stage Heart Disease Patients Show Significant Improvement After Adult Stem Cell Treatment; Interim Clinical Data From TheraVitae Study Presented At AHA Scientific Sessions
- Role of Cholesterol Lowering Drugs in Heart Failure Patients Evaluated in Yale Medical Center's Heart Study
- New Study Results Find That Patients Treated With Boosted INVIRASE, A Potent Anti-HIV Treatment, Showed No Significant Resistance to Protease Inhibitors
 |
 |
User Comments (0)
RSS Feeds